CXCR4 and AL amyloidosis: In recent years, many agents targeting SDF-1 and CXCR4 axis have been developed for clinical use [18–20], and one drug, AMD3100 (plerixafor or Mozobil) was approved for mobilization of hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma patients [28, 29].